서브메뉴
검색
Optimizing the Physicochemical Properties of RNA Nanoparticles for Controllable Drug Release, Hydrophobic Drug Encapsulation and Enhanced Cancer Targeting- [electronic resource]
Optimizing the Physicochemical Properties of RNA Nanoparticles for Controllable Drug Release, Hydrophobic Drug Encapsulation and Enhanced Cancer Targeting- [electronic resource]
상세정보
- 자료유형
- 학위논문파일 국외
- 최종처리일시
- 20240214101940
- ISBN
- 9798380200196
- DDC
- 616.99
- 저자명
- Xu, Congcong.
- 서명/저자
- Optimizing the Physicochemical Properties of RNA Nanoparticles for Controllable Drug Release, Hydrophobic Drug Encapsulation and Enhanced Cancer Targeting - [electronic resource]
- 발행사항
- [S.l.]: : The Ohio State University., 2020
- 발행사항
- Ann Arbor : : ProQuest Dissertations & Theses,, 2020
- 형태사항
- 1 online resource(239 p.)
- 주기사항
- Source: Dissertations Abstracts International, Volume: 85-03, Section: B.
- 주기사항
- Advisor: Guo, Peixuan.
- 학위논문주기
- Thesis (Ph.D.)--The Ohio State University, 2020.
- 사용제한주기
- This item must not be sold to any third party vendors.
- 초록/해제
- 요약The advancement of RNA nanotechnology in the past decade demonstrated its potentials as a new generation of drug for cancer treatment. However, nanoparticles encounter series of obstacles for successful drug delivery such as non-specific distribution, low release efficiency, heavy liver accumulation and other biological barriers. To address these issues for efficacious treatment, the RNA nano-delivery platform was engineered in terms of physical properties and chemistry characteristics to achieve favorable biodistribution, controlled drug release and enhanced cancer targeting.Chapter 1 gave an introduction of the RNA nanotechnology field and the current status of using RNA nanoparticles for biomedical applications. We discussed some key aspects of the pharmacokinetics of RNA nanomedicine including its distribution and elimination. Then we mentioned the challenges and limitations of RNA nanotechnology field which may hinder the clinical translation of this technology. In the following chapters, we further advanced RNA nanoplatform in order to address the abovementioned challenges.Chapter 2 described a controlled release scheme on RNA pyramid nanoparticles where the release of cargo could be cleaved from RNA nanocarrier with ease under the external light trigger. Chapter 3 showed the importance of controlling the surface chemistry of nanocage by encapsulation of hydrophobic molecules, which played a key role in reducing the non-specific interactions with cells and vital organs. Then we developed multivalent targeting strategy using MTX on RNA 3WJ nanoparticles as discussed in Chapter 4. Ligand valency has been manipulated to control the cancer targeting and biodistribution profile of RNA-MTX nanoparticles. In Chapter 5, we described a similar strategy in using multivalent small molecule DCL as ligands for specific PSMA targeting. The RNA nanoparticles were exploited for PET/CT imaging of prostate cancer with high specificity and sensitivity, providing image-guided therapy of prostate cancer. These studies focused on building up a relationship between the physicochemical properties of RNA nanoparticles with their pharmacokinetic profiles and pharmacological effects.In summary, with a more comprehensive understanding of how these characteristics regulate the performance of RNA nanoparticles, we will be able to improve the RNA nano-delivery system for optimized drug delivery and precision treatment.
- 일반주제명
- Pharmaceutical sciences.
- 일반주제명
- Oncology.
- 일반주제명
- Nanotechnology.
- 일반주제명
- Genetics.
- 키워드
- Cancer treatment
- 키워드
- Drug delivery
- 키워드
- Pharmacokinetics
- 키워드
- Nanomedicine
- 기타저자
- The Ohio State University Pharmaceutical Sciences
- 기본자료저록
- Dissertations Abstracts International. 85-03B.
- 기본자료저록
- Dissertation Abstract International
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008240612s2020 us |||||||||||||||c||eng d■001000016935500
■00520240214101940
■006m o d
■007cr#unu||||||||
■020 ▼a9798380200196
■035 ▼a(MiAaPQ)AAI30725443
■035 ▼a(MiAaPQ)OhioLINKosu1589810873310799
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a616.99
■1001 ▼aXu, Congcong.
■24510▼aOptimizing the Physicochemical Properties of RNA Nanoparticles for Controllable Drug Release, Hydrophobic Drug Encapsulation and Enhanced Cancer Targeting▼h[electronic resource]
■260 ▼a[S.l.]:▼bThe Ohio State University. ▼c2020
■260 1▼aAnn Arbor :▼bProQuest Dissertations & Theses, ▼c2020
■300 ▼a1 online resource(239 p.)
■500 ▼aSource: Dissertations Abstracts International, Volume: 85-03, Section: B.
■500 ▼aAdvisor: Guo, Peixuan.
■5021 ▼aThesis (Ph.D.)--The Ohio State University, 2020.
■506 ▼aThis item must not be sold to any third party vendors.
■520 ▼aThe advancement of RNA nanotechnology in the past decade demonstrated its potentials as a new generation of drug for cancer treatment. However, nanoparticles encounter series of obstacles for successful drug delivery such as non-specific distribution, low release efficiency, heavy liver accumulation and other biological barriers. To address these issues for efficacious treatment, the RNA nano-delivery platform was engineered in terms of physical properties and chemistry characteristics to achieve favorable biodistribution, controlled drug release and enhanced cancer targeting.Chapter 1 gave an introduction of the RNA nanotechnology field and the current status of using RNA nanoparticles for biomedical applications. We discussed some key aspects of the pharmacokinetics of RNA nanomedicine including its distribution and elimination. Then we mentioned the challenges and limitations of RNA nanotechnology field which may hinder the clinical translation of this technology. In the following chapters, we further advanced RNA nanoplatform in order to address the abovementioned challenges.Chapter 2 described a controlled release scheme on RNA pyramid nanoparticles where the release of cargo could be cleaved from RNA nanocarrier with ease under the external light trigger. Chapter 3 showed the importance of controlling the surface chemistry of nanocage by encapsulation of hydrophobic molecules, which played a key role in reducing the non-specific interactions with cells and vital organs. Then we developed multivalent targeting strategy using MTX on RNA 3WJ nanoparticles as discussed in Chapter 4. Ligand valency has been manipulated to control the cancer targeting and biodistribution profile of RNA-MTX nanoparticles. In Chapter 5, we described a similar strategy in using multivalent small molecule DCL as ligands for specific PSMA targeting. The RNA nanoparticles were exploited for PET/CT imaging of prostate cancer with high specificity and sensitivity, providing image-guided therapy of prostate cancer. These studies focused on building up a relationship between the physicochemical properties of RNA nanoparticles with their pharmacokinetic profiles and pharmacological effects.In summary, with a more comprehensive understanding of how these characteristics regulate the performance of RNA nanoparticles, we will be able to improve the RNA nano-delivery system for optimized drug delivery and precision treatment.
■590 ▼aSchool code: 0168.
■650 4▼aPharmaceutical sciences.
■650 4▼aOncology.
■650 4▼aNanotechnology.
■650 4▼aGenetics.
■653 ▼aCancer treatment
■653 ▼aDrug delivery
■653 ▼aBiological barriers
■653 ▼aPharmacokinetics
■653 ▼aNanomedicine
■690 ▼a0572
■690 ▼a0992
■690 ▼a0652
■690 ▼a0369
■71020▼aThe Ohio State University▼bPharmaceutical Sciences.
■7730 ▼tDissertations Abstracts International▼g85-03B.
■773 ▼tDissertation Abstract International
■790 ▼a0168
■791 ▼aPh.D.
■792 ▼a2020
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T16935500▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.
■980 ▼a202402▼f2024
